Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Posts 64 Percent Rise in Fiscal Q2 Revenue as Icoria Ag Line Winds Down and Erases Profits

NEW YORK (GenomeWeb News) — Clinical Data today said fiscal second-quarter 2007 revenues increased 64 percent as R&D spending on vilazodone studies rose 54 percent and profit turned swung to a loss.
Total receipts for the three months ended Sept. 30 increased to $19.2 million from $11.7 million year over year.
Clinical Data said revenues slid back $4 million from the previous quarter in 2006, however, because of the “final wind down” of subsidiary Icoria’s agricultural line. Clinical Data acquired Icoria in January for $11 million.
R&D spending on the company’s Vilazadone study increased to $2 million from
$1.3 million year over year.
Clinical Data posted a $8.1-million net loss from a $377,000 profit in the year-ago period.
The company said it paid $1.4 million in the second quarter in restructuring charges due to acquisition-related costs.  
Clinical Data said it had around $16.8 million in cash and cash equivalents as of Sept. 30.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.